an index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis c
Authors
abstract
conclusions in patients with chc g1 and receiving combination therapy, itpa snp-based index was an accurate and practical solution for prediction of severe anemia. background single-nucleotide polymorphisms (snp) in the inosine triphosphate pyrophosphatase (itpa) gene correlate with ribavirin (rbv)-induced anemia in patients with chronic hepatitis c (chc) receiving combination therapy. managing anemia is an early priority in the treatment process. objectives the aim was to develop a predictive index based on itpa snp status to identify chc patients at risk of anemia. patients and methods a total of 418 eligible east asian patients diagnosed with chc genotype 1 (g1) received combination therapy in this study. participant dna was genotyped for a functional itpa snp (c/c, a/a or c/a) on chromosome 20 at rs1127354. a predictive index was constructed by incorporating independent factors identified for severe anemia events (hemoglobin < 10 g/dl). areas under the receiver-operating characteristic curves (aucs) represented the diagnostic accuracies of the predictive index in randomly assigned development and validation cohorts. results multiple logistic regressions identified age (≥ 50 y: or = 9.7, 95% ci = 5.0 - 18.6), itpa rs1127354 (c/c: or = 3.3, 95% ci = 1.8 - 5.8) and baseline hemoglobin (< 14.0 g/dl: or 6.4, 95% ci = 3.3 - 12.1; 14.0 - 14.9: or = 2.4, 95% ci = 1.2 - 4.6) as predictors of severe anemia throughout the treatment. for severe anemia, the predictive index incorporating age, itpa snp status and baseline hemoglobin yielded diagnostic accuracies (aucs) of 0.830 (95% ci = 0.783 - 0.871) in the development (n = 324) and 0.902 (0.826 - 0.925) in the validation (n = 81) cohorts.
similar resources
An Index to Predict Ribavirin-Induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C
BACKGROUND Single-nucleotide polymorphisms (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene correlate with ribavirin (RBV)-induced anemia in patients with chronic hepatitis C (CHC) receiving combination therapy. Managing anemia is an early priority in the treatment process. OBJECTIVES The aim was to develop a predictive index based on ITPA SNP status to identify CHC patients at r...
full textModeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.
Ribavirin remains an important component of hepatitis C treatment in certain clinical scenarios, but it causes hemolytic anemia. A quantitative understanding of the ribavirin exposure-anemia relationship is important in dose individualization/optimization. We developed a model relating ribavirin triphosphate (RTP) exposure in red blood cells (RBCs), RBC lifespan, feedback regulation of RBC prod...
full textPolymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
Ribavirin (RBV)-induced anemia is a serious side effect of pegylated interferon (PEG-IFN) plus RBV therapy which is the standard care most effective for hepatitis C virus (HCV) infection. In the present study, we investigated the association of inosine triphosphate pyrophosphatase (ITPA) genotypes with RBV-induced hemoglobin (Hb) reduction in HCV patients treated with PEG-IFN/RBV therapy. The g...
full textImpact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
Chronically hepatitis C virus (HCV) infects about 180 million people worldwide and it is a major cause of serious liver disease. As sustained virological response (SVR) to anti-HCV therapy avoids progression of liver fibrosis, decreases the risk of hepatocellular carcinoma and improve the survival of patients, antiviral therapy is considered as a crucial option in the management of chronic HCV ...
full textFactors influencing therapeutic response to peginterferron plus ribavirin in the different genotypes of chronic hepatitis C
Abstract Background: Different factors like age, sex, route of infection, initial viral load, levels of liver function tests and genotypes may affect response to treatment in patients with chronic hepatitis C. The purpose of this study was to determine the role of these factors in the treatment of these patients. Methods: From 2004 to 2012, different genotypes of chronic HCV (Hepatitis C ...
full textIFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C
Although, the treatment of chronic hepatitis C (CHC) greatly improved with the use of direct antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many patients, worldwide. The intra-hepatic level of expression of interferon stimulated genes (ISGs) and the rs12979860 CC genotype located within IFNL3 have been associated with sustained virological response (SVR), ...
full textMy Resources
Save resource for easier access later
Journal title:
hepatitis monthlyجلد ۱۵، شماره ۳، صفحات ۰-۰
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023